文献速递肾小球疾病

抢先免疫抑制治疗无症状血清学再激活或可减少狼疮肾炎肾脏复发:一项队列研究

Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis: a cohort study.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

该回顾性队列分析纳入138次无症状血清学再激活(ASR)事件,其中53次抢先增加免疫抑制、85次未调整治疗。抢先治疗与更优的无肾脏复发生存相关,且未发生肾脏复发者肾功能保留更好,但胃肠道副作用增加,感染率无差异。

要点

  • 抢先中度增加免疫抑制可降低ASR后的肾脏复发风险(HR 0.3)。
  • 抢先治疗组无肾脏复发生存率在6、12、24个月均优于对照组。
  • 未发生肾脏复发的抢先治疗者eGFR斜率更好,但胃肠道副作用增加。

核心结论

  • 对狼疮肾炎患者ASR抢先中度增加免疫抑制可能减少肾脏复发并有利于长期肾功能。

研究设计与样本

  • 回顾性分析138次ASR事件,其中53次抢先增加免疫抑制,85次未调整治疗。

主要发现

  • 无肾脏复发生存率抢先组6、12、24个月分别为99%、92%、90%,对照组分别为94%、69%、64%,P=0.011。
  • 无肾外复发生存率两组相似。
  • 未发生肾脏复发的抢先治疗者eGFR斜率为+0.54±0.43 mL/min/1.73 m2/年,对照组发生和未发生肾脏复发者分别为-2.11±0.50和-1.00±0.33 mL/min/1.73 m2/年,P=0.001和0.012。
  • 抢先治疗与MMF相关胃肠道副作用发生率增加相关(P=0.031),感染率两组无差异。

关键数值与推荐

  • 抢先免疫抑制方案:泼尼松龙增至约0.5 mg/kg/天;已用MMF者增至1.5 g/天,已用AZA者增至100 mg/天。

临床怎么用

  • 对狼疮肾炎患者出现ASR时可考虑抢先中度增加免疫抑制,但需监测MMF相关胃肠道副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serological activity may precede clinical flares of lupus nephritis (LN) but the management of asymptomatic serological reactivation (ASR) remains undefined. METHODS: We conducted a retrospective analysis of 138 episodes of ASR, which included 53 episodes in which immunosuppression was increased preemptively and 85 episodes in which treatment was unaltered. Preemptive immunosuppressive treatment comprised increasing the dose of prednisolone to ∼0.5 mg/kg/day, and in patients already on mycophenolate mofetil (MMF) or azathioprine (AZA), increasing the dose to 1.5 g/day and 100 mg/day, respectively. RESULTS: Thirty-four episodes of renal flare occurred during follow-up (88.8 ± 77.3 and 82.8 ± 89.7 months in the preemptive group and controls, respectively), following 5 (9.4%) of preemptively treated ASR and 27 (31.8%) of untreated ASR [hazard ratio 0.3 (confidence interval 0.1-0.7), P = 0.012]. Preemptive treatment was associated with superior survival free of renal relapse (99, 92 and 90% at 6, 12 and 24 month, respectively, compared with 94, 69 and 64% in controls; P = 0.011), whereas survival rate free of extrarenal relapse was similar in the two groups. Preemptively treated patients who did not develop renal flares showed better renal function preservation (estimated glomerular filtration rate slope +0.54 ± 0.43 mL/min/1.73 m2/year, compared with -2.11 ± 0.50 and -1.00 ± 0.33 mL/min/1.73 m2/year, respectively, in controls who did and did not develop subsequent renal flares; P = 0.001 and 0.012, respectively). Preemptive treatment was associated with an increased incidence of gastrointestinal side effects attributed to MMF (P = 0.031), whereas infection rate did not differ between the two groups. CONCLUSION: A preemptive moderate increase of immunosuppression for ASR in LN patients may reduce renal flares and confer benefit to long-term renal function.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yap DYH, Kwan LPY, Ma MKM, et al. Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis: a cohort study. Nephrol Dial Transplant. 2019. PMID: 29509932. doi:10.1093/ndt/gfy024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。